Cerroni L, Volkenandt M, Rieger E, Soyer H P, Kerl H
Department of Dermatology, University of Graz, Austria.
J Invest Dermatol. 1994 Feb;102(2):231-5. doi: 10.1111/1523-1747.ep12371768.
The interchromosomal 14;18 translocation occurs in approximately 70-80% of follicular lymphomas and in a lower proportion of high-grade non-Hodgkin lymphomas of the lymph nodes. This translocation results in the fusion of the bcl-2 oncogene on chromosome 18 with immunoglobulin heavy chain genes on chromosome 14, and in the expression of higher amounts of normal bcl-2 protein. We studied bcl-2 expression in biopsies of 108 patients with benign and malignant cutaneous lymphoproliferative diseases (B-cell lymphoma, primary cutaneous, 42; secondary cutaneous, 21; primary cutaneous T-cell lymphoma, 21; B-cell pseudolymphoma, 24), using a monoclonal anti-bcl-2 antibody on paraffin-embedded tissue sections, bcl-2 protein was detected immunohistochemically in 16 of 63 cases of cutaneous B-cell lymphoma, whereas cutaneous T-cell lymphomas and B-cell pseudolymphomas were negative. The proportion of bcl-2 protein expression was significantly higher in secondary (11/21) than in primary cutaneous B-cell lymphomas (5/42; chi 2 test, p < 0.001). Biopsies from 25 of these patients (B-cell lymphoma, 22; B-cell pseudolymphoma, three) were analyzed previously on the molecular level for the t(14;18), using polymerase chain reaction amplification of DNA obtained from paraffin-embedded sections. In four of 11 cases of bcl-2 protein-positive B-cell lymphoma (primary, one; secondary, three) the t(14;18) was detected by polymerase chain reaction. All other cases of B-cell lymphoma, including seven cases where bcl-2 protein was detected by immunohistology, and B-cell pseudolymphoma were negative. These results demonstrate: 1) bcl-2 protein is expressed in a small portion of cutaneous B-cell lymphomas; 2) bcl-2 protein expression is significantly more frequent in secondary than in primary cutaneous B-cell lymphoma; 3) only approximately one-third of cases expressing the bcl-2 protein are characterized also by the t(14;18). bcl-2 protein expression might indicate that the cutaneous manifestation of the lymphoma represents a secondary spread from a node-based lymphoma.
染色体间14;18易位发生在约70 - 80%的滤泡性淋巴瘤以及较低比例的淋巴结高级别非霍奇金淋巴瘤中。这种易位导致18号染色体上的bcl - 2癌基因与14号染色体上的免疫球蛋白重链基因融合,并使正常bcl - 2蛋白表达量增加。我们使用单克隆抗bcl - 2抗体对108例良性和恶性皮肤淋巴增殖性疾病(原发性皮肤B细胞淋巴瘤42例、继发性皮肤淋巴瘤21例、原发性皮肤T细胞淋巴瘤21例、B细胞假性淋巴瘤24例)的活检组织进行研究,在石蜡包埋组织切片上通过免疫组织化学检测bcl - 2蛋白。在63例皮肤B细胞淋巴瘤中有16例检测到bcl - 2蛋白,而皮肤T细胞淋巴瘤和B细胞假性淋巴瘤均为阴性。bcl - 2蛋白表达比例在继发性皮肤B细胞淋巴瘤(11/21)中显著高于原发性皮肤B细胞淋巴瘤(5/42;卡方检验,p < 0.001)。之前对其中25例患者(B细胞淋巴瘤22例、B细胞假性淋巴瘤3例)的活检组织进行了分子水平的t(14;18)分析,采用聚合酶链反应扩增从石蜡包埋切片获得的DNA。在11例bcl - 2蛋白阳性的B细胞淋巴瘤(原发性1例、继发性3例)中有4例通过聚合酶链反应检测到t(14;18)。所有其他B细胞淋巴瘤病例,包括7例通过免疫组织学检测到bcl - 2蛋白的病例,以及B细胞假性淋巴瘤均为阴性。这些结果表明:1)bcl - 2蛋白在一小部分皮肤B细胞淋巴瘤中表达;2)bcl - 2蛋白表达在继发性皮肤B细胞淋巴瘤中比原发性更常见;3)只有约三分之一表达bcl - 2蛋白的病例也具有t(14;18)特征。bcl - 2蛋白表达可能表明淋巴瘤的皮肤表现代表了基于淋巴结的淋巴瘤的继发性扩散。